Modality
mAb
MOA
HPK1i
Target
TIGIT
Pathway
Cell Cycle
ETUCNarcolepsy
Development Pipeline
Preclinical
Feb 2023
→ Jul 2028
PreclinicalCurrent
NCT05636779
2,043 pts·ET
2024-08→TBD·Not yet recruiting
NCT06025401
2,954 pts·UC
2023-02→2028-07·Terminated
4,997 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-07-162.3y awayInterim· UC
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Termina…
Preclinical
Not yet…
Catalysts
Interim
2028-07-16 · 2.3y away
UC
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05636779 | Preclinical | ET | Not yet recr... | 2043 | OS |
| NCT06025401 | Preclinical | UC | Terminated | 2954 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT |